Extremely Late Complete AV Block After TAVR: ECG Clues and Correction With Left Bundle Branch Pacing.

Pacing Clin ElectrophysiolMar 17, 2026 (epub)
Case ReportCardiologyOpen access

Ngoc Dung Kieu, Cao Dat Tran, Le Uyen Phuong Tran et al.

✦ AI-curated · Sources linked

Case in brief

A 63-year-old man developed complete atrioventricular block 17 months after transcatheter aortic valve replacement with an Evolut-R 29 mm valve. Serial ECGs had shown progressive conduction abnormalities, from left anterior fascicular block to complete left bundle branch block with first-degree AV block. Electrophysiological testing showed AH and HV intervals of 75 ms and 78 ms, and prolonged ambulatory monitoring detected intermittent high-grade block. Left bundle branch pacing provided physiologic ventricular activation and corrected the conduction abnormalities; symptoms resolved and pacing parameters remained stable at follow-up.

What made this case unusual

The complete AV block occurred 17 months after TAVR, following progressive ECG changes that preceded the clinical presentation.

Diagnostic / clinical pearl

Progressive ECG abnormalities after TAVR may precede late high-grade AV block; this case supports prolonged rhythm surveillance when such changes are present.

Why it matters

Left bundle branch pacing both provided reliable pacing and corrected ventricular conduction abnormalities in this patient.

Source

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.